Home › Turner Syndrome › NCT06834594

Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome

Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome: A Non-randomized Prospective Trial (The BOOST Study)

Who can join

Ages 12 to 20 · Women

Inclusion Criteria:

* Diagnosis of Turner Syndrome and Primary Ovarian Insufficiency.
* Prescribed adult dosing\* of transdermal or oral estradiol for estrogen replacement therapy.

  \*Adult dosing of will be defined per published clinical practice guidelines from the 2023 International Turner Syndrome Meeting (i.e. 50-200μg/day of transdermal estradiol, or (i.e. 50-200μg/day of transdermal estradiol or 2-4mg/day oral estradiol).
* Have achieved menarche.

Exclusion Criteria:

* Disclosure of sexual activity and desire for contraception.
* Having a levonorgestrel-releasing intrauterine device or etonogestrel arm implant in place.
* Having received depot medroxyprogesterone within one year prior to study recruitment.
* Non-English or non-Spanish speaking.

About the study

This is a single-site open label non-randomized study comparing effects of sequential versus continuous use of progesterone supplementation amongst Turner Syndrome (TS) patients with primary ovarian insufficiency (POI) prescribed hormone replacement therapy (HRT).

What is being tested

• Micronized progesterone 200 MG (drug)
• Micronized Progesterone 100 MG (drug)

Sponsor: Children's Mercy Hospital Kansas City · Participants: 40 · Started: Jul 31, 2025

Contact the study team

• Allie Ranallo · Phone: +1-816-394-7534
• Andrea Manlove · Phone: +1-816-731-7326

Official record on ClinicalTrials.gov — NCT06834594

Locations in the U.S.

Conditions

• Turner Syndrome
• Primary Ovarian Insufficiency

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.